F
43.29
-0.38 (-0.87%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Korro Bio, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.5
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.50 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 6.44% |
| 机构持股比例 | 91.36% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 30 Sep 2024 | 368,085 |
| 72 Investment Holdings, Llc | 30 Sep 2024 | 276,831 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 153.00 (Raymond James, 253.43%) | 购买 |
| 中 | 122.50 (182.98%) | |
| 低 | 105.00 (RBC Capital, 142.55%) | 购买 |
| 平均值 | 125.75 (190.48%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 62.67 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Nov 2024 | 115.00 (165.65%) | 购买 | 52.31 |
| 13 Nov 2024 | 115.00 (165.65%) | 购买 | 55.01 | |
| Jones Trading | 18 Nov 2024 | 130.00 (200.30%) | 购买 | 46.63 |
| RBC Capital | 21 Oct 2024 | 105.00 (142.55%) | 购买 | 75.86 |
| Raymond James | 21 Oct 2024 | 153.00 (253.43%) | 购买 | 75.86 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合